Concepedia

Author

Claus-Henning Köhne

Klinikum Oldenburg

Also Known As

Claus-Henning Kohne, Claus-Henning Köhne

16

Publications

7.9K

Citations

12

H-Index

7

Concepts

All Affiliations

Klinikum OldenburgUniversity Hospital Carl Gustav CarusUniversity Hospital of BernMerck (Germany)KU Leuven
CK

About

Claus-Henning Köhne is an author at Klinikum Oldenburg specializing in breast cancer, radiation oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

498

2

Medicine

1

1

498

3

Cancer Therapeutics

1

1

498

4

Clinical Trials

1

1

498

5

Breast Cancer

1

1

498

Claus-Henning Köhne

×

9

Publications

7.5K

Citations

9

H-Index

YearCitations

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre,

New England Journal of Medicine

2009

3.8K

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Eric Van Cutsem, Claus-Henning Köhne, István Láng,

Journal of Clinical Oncology

2011

1.9K

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Eric Van Cutsem, Heinz‐Josef Lenz, Claus-Henning Köhne,

Journal of Clinical Oncology

2015

783

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch, Richard D. Gelber, Martine Piccart,

The Lancet

2013

498

Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma

Eric Van Cutsem, Emilio Bajetta, Juan W. Valle,

Journal of Clinical Oncology

2011

161

Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001

Jürg Bernhard, Daniel Dietrich, Werner Scheithauer,

Journal of Clinical Oncology

2008

101

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Josep Tabernero, Rocio García‐Carbonero, James T. Cassidy,

Clinical Cancer Research

2013

87

Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials

Charles D. Blanke, Brian M. Bot, David M. Thomas,

Journal of Clinical Oncology

2011

77

Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin

István Láng, Claus-Henning Köhne, Gunnar Folprecht,

European Journal of Cancer

2012

70

Page 1